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Abstract
Background: In 1998, following the detection of variant Creutzfeldt-Jakob disease (vCJD) in the UK, Belgium
installed a surveillance system for Creutzfeldt-Jakob disease (CJD). The objectives of this system were to identify
vCJD cases and detect increases in CJD incidence. Diagnostic confirmation of CJD is based on autopsy after referral
by neurologists. Reference centres perform autopsies and report to the surveillance system. The aim of this study
was to assess whether the system met its objectives and to assess its acceptability.
Methods: For 1999–2010, we linked surveillance data with hospital discharge data. We calculated the proportion of
CJD suspected patients who died in hospitals and were captured by the surveillance system. We surveyed
stakeholders on knowledge of the surveillance system, referral practices and acceptability. We compared
proportions using the chi-square test and investigated variables associated with capture using a multivariable
logistic regression model.
Results: On average 60 % of hospitalised patients who died with suspected CJD were captured by the surveillance
system. This proportion did not significantly differ over the years (p = 0.1). The odds of capture significantly
decreased with every 1 year increase in age (OR = 0.95, 95 % CI 0.92–0.98, p = 0.001). Eleven percent of surveyed
neurologists would not refer suspect vCJD cases for autopsy, nor contact a reference centre for diagnostic support.
Sixty-one percent of surveyed neurologists were not familiar with the surveillance system. Awareness of the
existence of the system did not impact referral behaviour (p = 0.18). CJD and vCJD surveillance were considered
important by the majority of stakeholders.
Conclusions: Although 40 % of the suspect CJD cases were not referred for autopsy, our data suggest that the
Belgian CJD surveillance system meets one of its main objectives: it can detect changes in CJD incidence. However,
we do not have sufficient evidence to conclude that the system meets its second objective of detecting vCJD cases
arising in Belgium. Although not well known, the system was considered acceptable by its stakeholders.
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Background
Creutzfeldt-Jakob disease (CJD) is a transmissible spongi-
form encephalopathy (TSE) or prion disease that
causes progressive brain degeneration. Estimated inci-
dence worldwide ranges from 1 to 1.5 cases per million
per year [1, 2]. CJD is always fatal. No therapy or vac-
cine is available. Four forms are known according to
their aetiology: sporadic (sCJD), familial (fCJD), iatro-
genic (iCJD) and variant (vCJD). Worldwide, the spor-
adic form accounts for 87 % of CJD cases, the familial
for 8 % and the iatrogenic for less than 5 % [2]. Definite
diagnosis of CJD is based on identification of the clas-
sical neuropathological triad: neuronal loss, gliosis and
spongiform degeneration, and on identification of
prion protein deposition in the brain. Therefore defini-
tive diagnosis requires post-mortem neuropathological
examination. Differentiation of vCJD and the other CJD
forms also requires autopsy.
In 1996, vCJD was first detected in the UK [3]. This
form of CJD was soon linked to bovine spongiform en-
cephalopathy (BSE), a related disease that had been
causing an epidemic in cattle in the UK since 1986. Evi-
dence suggested that human vCJD cases were infected
through consumption of contaminated animal products
[4]. Variant CJD cases differ from other CJD cases. The
patient’s median age at death is 28 years [5], compared
with 62–68 years for sporadic CJD [6–8]. In addition,
the median disease duration among vCJD cases is
14 months [5], compared with 4–6 months for other
CJD’s [6–8]. Between 1995 and 2013, 228 people world-
wide died from vCJD, of whom 177 had lived in the UK
[9]. The peak of the epidemic was reached in 2000, and
the annual incidence has been decreasing since [9, 10].
Although the appearance of a smaller second peak in
the future cannot be excluded [11], the public health im-
portance of a vCJD pandemic has decreased in the
2000s.
In 1998, Belgium initiated a surveillance system for all
forms of CJD. Initially, the objective of this surveillance
was to detect vCJD cases in order to identify risk factors,
trace back the source of infection, identify possible cases
sharing the same exposure and prevent secondary trans-
mission through blood products and transplants. The
second objective was to detect increases in the CJD inci-
dence, which could be an early warning signal for the
emergence of new prion diseases or for new modes of
transmission [12, 13]. Up to December 2014, no vCJD
case has been diagnosed in Belgium and the decrease in
public health relevance may have led to a decrease in
the proportion of clinically suspected CJD cases referred
for autopsy [7].
We evaluated if the Belgian CJD surveillance system is
capable of reaching its objectives to detect vCJD cases
and significant increases in the CJD incidence. We also




The 1998 Rotterdam criteria, with a 2010 modification,
classify sporadic, familial and iatrogenic CJD [14–16]
(Table 1). A possible case requires clinical evidence. Prob-
able cases require additional electroencephalogram (EEG),
magnetic resonance imaging (MRI) or laboratory suggest-
ive evidence. Confirmed cases require neuropathological
confirmation.
The 2000 UK criteria classify vCJD cases [17] (Table 1).
Possible vCJD cases rely on clinical evidence. Probable
vCJD cases require an additional characteristic brain
magnetic resonance imaging (MRI) or positive tonsil bi-
opsy. Confirmed vCJD cases require neuropathological
confirmation.
For the purpose of this evaluation, we defined suspect
CJD cases as patients that died with the suspicion of
CJD, regardless of case classification criteria.
Organization of the surveillance system
The Belgian CJD surveillance system covers probable
and confirmed cases of CJD in people with the Belgian
nationality. Seven academic centres of neurology/neuro-
pathology are appointed as CJD reference centres. The
Scientific Institute of Public Health (WIV-ISP) acts as
the coordinator and maintains the surveillance database
[8]. Neurologists that suspect CJD in a patient can refer
the patient to a reference centre, which reports probable
cases. Four of these centres can confirm cases by aut-
opsy. They report on all autopsies of suspect CJD cases,
regardless of whether the CJD diagnosis was confirmed
or not. The surveillance system reimburses these autop-
sies. In cases where the patient or his family refuses re-
ferral to a reference centre, the neurologist can report
the probable case. Reference centres and neurologists re-
port cases and autopsies using a 4-page paper form. The
form collects information on personal and demographic
characteristics, treating physicians, signs, symptoms, re-
sults of diagnostic procedures (including stored speci-
mens) and risk factors. The completed form is sent by
regular mail to the WIV-ISP, which is responsible for
collecting, storing and processing the data. Data are ana-
lysed yearly and a report is published on the WIV-ISP
website.
Analysis and completeness of surveillance data
For 1998–2012, we analysed the Belgian surveillance
data. We calculated the annual number of reported aut-
opsies, the reported probable and confirmed CJD cases,
the yearly incidence of probable and confirmed CJD
cases and the age-standardized yearly incidence of
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probable and confirmed CJD cases according to the age
distribution in the World Health Organization (WHO)
World standard population [18]. We described the final
diagnosis of patients that were found negative for CJD in
the autopsy.
Data completeness was assessed for all reported autop-
sies and probable cases for the years 1998–2012 for the
following variables: postcode, sex, date of birth, date of
death, disease duration, symptoms at onset, EEG result,
14-3-3 protein test result, MRI result, prion protein
Table 1 Diagnostic criteria CJD based on the Rotterdam criteria and the UK criteria
SPORADIC CDJ
Criteria
I Rapidly progressive dementia
II A Myoclonus
B Visual or cerebellar problems
C Pyramidal or extrapyramidal features
D Akinetic mutism
III CJD-typical periodic sharpwave complexes in electroencephalography
IVa High signal in caudate/putamen on MRI brain scan
Classification
Confirmed sporadic CJD Neuropathological/immunocytochemical confirmation
Probable sporadic CJD I and 2 of II and III OR I and 2 of II and IVa OR possible sporadic CJD and positive 14-3-3
Possible sporadic CJD I and 2 of II and duration < 2 years
aAs of 2010
IATROGENIC CJD
Progressive cerebellar syndrome in a pituitary hormone recipient OR sporadic CJD with a recognised exposure risk, e.g., dura mater transplant
FAMILIAL CJD




I A Progressive neuropsychiatric disorder
B Duration of illness > 6 months
C Routine investigations do not suggest an alternative diagnosis
D No history of potential iatrogenic exposure
E No evidence of a familial form of TSE
II A Early psychiatric featuresa
B Persistent painful sensory symptomsb
C Ataxia
D Myoclonus or chorea or dystonia
E Dementia
III A EEG does not show the typical appearance of sporadic CJD in the early stages of illnessc
B Bilateral pulvinar high signal on MRI scan
IV A Positive tonsil biopsy
Classification
Confirmed variant CJD IA and neuropathological confirmation of vCJDd
Probable variant CJD I and 4/5 of II and IIIA and IIIB OR 1 and IVA
Possible variant CJD I and 4/5 of II and IIIA
aDepression, anxiety, apathy, withdrawal, delusions
bIncluding both frank pain and/or dysaesthesia
cGeneralised triphasic periodic complexes at approximately one per second
dSpongiform change and extensive PrP deposition with florid plaques, throughout the cerebrum and cerebellum
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(PrP) gene analysis result and familial history of CJD.
Data completeness was defined as the proportion of data
that is not stated as ‘missing’ or ‘unknown’. We calcu-
lated the annual completeness per variable, the annual
completeness over all variables and the total complete-
ness per variable over the period 1998–2012. For the
years 1998–2012, we looked for trends in annual com-
pleteness per variable and in annual completeness over
all variables.
Estimation of suspect cases captured by the surveillance
system
For 1999–2010, Belgian surveillance data were linked
with hospital discharge data. Records were linked based
on age, gender and postal code. Records with more than
one possible link were excluded. We calculated the an-
nual proportion of suspect cases that died in hospital
with CJD as primary or secondary diagnosis (ICD 9
code: 046.1) for which autopsy was performed in a refer-
ence centre. We assessed differences in the proportion
of autopsies performed between the year of death, the
province, gender and those with CJD as primary or as
secondary diagnosis. The effect of age of the patient on
the performance of an autopsy was assessed. For 1999–
2010, we looked for a trend in the proportion of suspect
cases that died in hospitals and underwent autopsy.
These procedures were repeated for suspect cases that
died in hospital with CJD as primary or secondary diagno-
sis and were captured by the surveillance system either
through an autopsy either as a probable case.
Online surveys
We developed three online surveys: for Belgian neurol-
ogists, for persons responsible for the reference centres
and for public health officials.
Neurologists were invited through two professional or-
ganizations. They were asked about their knowledge of
the surveillance system, their referral behaviour and
their perception of the importance of vCJD and CJD sur-
veillance. They were also asked about changes in partici-
pation or interest in CJD surveillance since 1998, on
their reporting preferences and on limitations of the
system.
We sent invitations by email to the persons respon-
sible for the reference centres. They were asked about
their perception of the importance of vCJD and CJD sur-
veillance, on their reporting preferences and on limita-
tions of the system.
We contacted public health officials through their
governmental organisations and asked them to fur-
ther distribute the email. They were asked about their
perception of the importance of vCJD and CJD
surveillance.
Ethics committee statement
The Ethics Committee of the Antwerp University
Hospital reviewed the study and granted a waiver of
informed consent, as the date are collected within the
context of health surveillance as requested by European
legislation.
Statistical analysis
Data were analysed using Microsoft Excel and Stata 12
(StataCorp). We compared proportions using the chi-
square test and checked for trends using the Cuzick
non-parametric test for trends. The effect of a 1 year in-
crease in age on the performance of an autopsy and on
total capture by the surveillance system was assessed by
calculating odds ratios (OR) and 95 % confidence inter-
vals (CI) in a logistic regression model. Variables associ-
ated with autopsy with a p-value <0.2 in the univariate
analysis were included in a backward stepwise multivari-
able logistic regression model. A similar model was built
for variables associated with total capture by the surveil-
lance system. A p-value <0.05 was considered significant.
Results
Belgian CJD surveillance 1998–2012
In 1998–2012, 304 autopsies of Belgian suspect CJD
cases were reported to the surveillance system. Of all
autopsies, 167 (55 %) resulted in CJD diagnosis. Of
these, 163 (98 %) were sCJD cases, three (1.4 %) fCJD
and one (0.6 %) iCJD. In addition, 42 probable CJD
cases, among which two probable fCJD cases, were also
reported to the system (Fig. 1). Recorded incidence
ranged from 0.5 to 2.1 cases per million inhabitants per
year (average 1.3), and age-standardized incidence ranged
from 0.2 to 1.4 cases per million inhabitants per year
(average 0.8) (Fig. 1).
Among the 137 (45 %) autopsies that were found
negative for CJD, 31 (23 %) were cases of Alzheimer’s
dementia, 18 (13 %) of dementia (not further specified),
16 (12 %) of Lewy body dementia, 8 (6 %) of encephalitis,
24 (18 %) had no final diagnoses and 40 (29 %) had vari-
ous other diagnoses.
Data quality
We calculated data completeness for 346 reports of aut-
opsies and probable cases. For 1998–2012, the annual
completeness over all variables ranged from 53 to 89 %
(data not shown). The variables with lowest total com-
pleteness over this period were MRI result (49 %) and
PrP gene analysis result (33 %). The variables with high-
est total completeness over this period were sex (100 %),
date of birth (97 %), date of death (96 %) and postal code
(91 %). Total completeness over this period of the other
variables ranged between 60 and 80 %. For 1998–2012, a
significant downward trend in annual completeness was
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observed in the following variables: symptoms at onset
(p = 0.004), EEG result (p = 0.023) and familial history of
CJD (p = 0.004). For 1998–2012, a significant upward
trend in annual completeness was observed in the fol-
lowing variables: date of birth (p = 0.034) and date of
death (p = 0.028). For the other variables we observed no
trend in annual completeness over the period 1998–
2012. The annual completeness over all variables de-
creased significantly from 1998 to 2012 (p = 0.024).
Estimation of suspect cases captured by the surveillance
system
In 1999–2010, the hospital discharge database contained
241 suspect cases. Of these, 122 (51 %) underwent an
autopsy in a reference centre. The annual proportion
ranged from 35 % in 2010 to 65 % in 2002 (Table 2),
with no trend (p = 0.14). In univariate analysis we did
not detect a significant difference in proportion referred
for autopsy between years (p = 0.65), province (p = 0.11),
gender (p = 0.74) and those with CJD as primary or as
secondary diagnosis (p = 0.22). The odds of undergoing
an autopsy significantly decreased with every 1 year in-
crease in age (OR 0.97, 95 % CI 0.94–0.99, p = 0.01).
Only the effect of age was significant in the multivariable
analysis (OR 0.97, 95 % CI 0.94–0.99, p = 0.01).
Out of 241 patients that died in hospital with CJD as a
primary or secondary diagnosis, 144 (60 %) were cap-
tured by the surveillance system (autopsy or probable
case). The annual proportion varied between 35 % in
2010 and 80 % in 2002 (Table 2). This proportion
showed a downward trend (p = 0.004). In univariate
analysis we did not detect a significant difference in this
proportion between years (p = 0.1), gender (p = 0.66) and
between groups with CJD as primary or as secondary
diagnosis (p = 0.15). We detected a significant difference
between the provinces (p = 0.023) and the odds of cap-
ture significantly decreased with every 1 year increase in
Fig. 1 CJD incidence and autopsy results of suspected CJD cases by case classification, 1998–2012, Belgium
Table 2 Annual suspect CJD cases by way of capture by the






























1999 15 9 (60) 10 (67) 5 (33)
2000 14 7 (50) 7 (50) 7 (50)
2001 19 10 (53) 14 (74) 5 (26)
2002 20 13 (65) 16 (80) 4 (20)
2003 24 14 (58) 17 (71) 7 (29)
2004 24 10 (42) 15 (63) 9 (37)
2005 17 8 (47) 10 (59) 7 (41)
2006 20 9 (45) 13 (65) 7 (35)
2007 25 15 (60) 15 (60) 10 (40)
2008 15 6 (40) 6 (40) 9 (60)
2009 17 10 (59) 10 (59) 7 (41)
2010 31 11 (35) 11 (35) 20 (65)
Total 241 122 (51) 144 (60) 97 (40)
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age (OR 0.95, 95 % CI 0.92–0.98, p = 0.001). Only the ef-
fect of age remained significant in the multivariable ana-
lysis (OR 0.95, 95 % CI 0.92–0.98, p = 0.001).
Survey response
We could not calculate response proportions for neurol-
ogists, because we did not have access to the email dis-
tribution lists of the organisation of neurologists. As a
proxy figure for the neurologists, we used the number of
registered neurologists available from the national insti-
tute for health insurance.
Of 533 neurologists registered in Belgium, 72 (14 %)
completed the survey. Of seven contacted reference cen-
tres, four (57 %) submitted a completed survey. Thirteen
public health officials completed the survey, since we
asked to forward the email within their organisations, no
response proportion could be calculated.
Survey results on referral behaviour of neurologists
Among the 72 neurologists who completed the survey,
28 (39 %) were aware of the existence of the surveillance
system. However, 61 (85 %) neurologists would refer all
suspect CJD cases or contact a reference centre for diag-
nostic support. Three neurologists (4 %) would only
refer vCJD cases. Among those who would not refer
cases nor contact a reference centre, three (38 %) were
unaware of the existence of the centres, and five (63 %)
did not see the added value of referral (Table 3). Being
aware of the existence of the surveillance system did
not impact the referral behaviour of the neurologists
(p = 0.18).
Survey results on acceptability and simplicity of the
surveillance system
The majority of stakeholders surveyed, including 41
(57 %) neurologists, three (75 %) responsibles of refer-
ence centres and 10 (77 %) public health officials, con-
sidered variant CJD surveillance important. The majority
of stakeholders surveyed, including 55 (76 %) neurolo-
gists, four (100 %) responsibles of reference centres and
11 (85 %) public health officials, considered CJD surveil-
lance important (Fig. 2). Nine (13 %) neurologists reported
a decrease in their participation or interest in CJD
surveillance.
Of 72 neurologists and reference centres, six (8 %) had
no opinion regarding reporting procedures, five (7 %)
preferred the currently used paper form and 65 (86 %)
preferred electronic reporting. Of the latter, 39 (51 %)
preferred an online questionnaire.
Among the 72 neurologists, 16 (22 %) emphasized the
need for better visibility of the system and regular feed-
back to the data providers.
Discussion
This evaluation indicated that in 1999–2010, a stable
proportion of suspect CJD cases who died in hospitals
underwent an autopsy in a reference centre or was cap-
tured by the surveillance system as either an autopsy or
a probable case. The proportion of suspect CJD cases
captured by the surveillance system showed a downward
trend. The older the suspected case was, the less likely
he was to have an autopsy performed or to be captured
by the surveillance system. Among neurologists who
completed the survey, 89 % would refer a vCJD case to a
reference centre or contact a reference centre for diag-
nostic support. In 1998–2012, data quality decreased.
The majority of stakeholders surveyed considered CJD
and vCJD surveillance important and preferred online
reporting. The main reported limitation to the system
was its lack of visibility and feedback to the neurologists.
Only 39 % of surveyed neurologists were aware of the
system’s existence.
A stable referral of suspect cases for autopsy is key for
detection of increases in CJD incidence that could be
the sign of an undetected event. Increases in the measured
incidence of sCJD over time have indeed previously been
attributed to enhanced surveillance [1, 8, 19, 20] and stud-
ies have shown that the proportion of suspect CJD cases
that is referred for autopsy, predicts the measured inci-
dence of CJD [21, 22]. Changes in the measured incidence
can therefore be caused by a non-stable yearly proportion
of suspect cases referred for autopsy or by a true change
Table 3 Knowledge of the Belgian CJD surveillance system and
referral practices reported by Belgian neurologists
Topic of the question Neurologists’ response Number Percent
Knowledge of the existence
of the surveillance system
(N = 72)
Yes 28 39
Referral behaviour in case
of suspected CJD (N = 72)
Do not refer or
contact for support
8 11






















Do not see the added
value
5 63
Legend: Knowledge of the Belgian CJD surveillance system and referral
practices as reported by Belgian neurologists (N = 72) in an online survey,
2013, Belgium
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in the incidence. Our data show that in Belgium for
1999–2010, the proportion of suspect cases referred for
autopsy was similar over the years, around 50 %. The pro-
portion of suspect cases captured by the surveillance sys-
tem as an autopsy or a probable case was also similar over
the years around 60 %. These findings suggest that in-
creases in the measured CJD incidence would very likely
reflect true increases in CJD incidence. Moreover, the sta-
bility between the Belgian provinces of the proportion of
suspect cases referred for autopsy, decreases the chance of
misidentifying geographical clusters due to locally in-
creased surveillance as previously reported in other
countries [6, 21, 22]. Our data did show a significant
downward trend in the proportion of suspect cases cap-
tured by the surveillance system. Although this trend has
not yet resulted in significant differences over the years, a
continuation of this trend will inevitably do so, so it is im-
portant to monitor referral in the future. The reason for
the decrease in capture by the surveillance system with in-
creasing age is not clear. Families may be more reluctant
in accepting an autopsy for an elderly person or doctors
may be less focussed on having a final diagnosis in these
cases. Although identifying the reason for this falls outside
the scope of our study, this decrease may result in an
underestimation of CJD in the older people and should be
investigated further. Thus, the surveillance system meets
one of its main objectives as it is likely to detect true in-
creases in CJD incidence in Belgium, but monitoring the
stability of the referral, both for autopsy as for the report-
ing of probable cases, remains essential.
Although the public health relevance of a vCJD epi-
demic has decreased in recent years and the surveillance
system is not well known, our investigation of neurolo-
gists’ referral behaviour suggests that they were still
aware of the importance of detecting vCJD cases and
contacting a reference centre. Among those neurolo-
gist that responded to the survey, the vast majority
(89 %) would refer suspect vCJD cases to a reference
centre or contact a reference centre. Moreover, the
younger age of vCJD patients and the longer disease
duration would render detection of vCJD cases by the
surveillance system more likely, even if the neurolo-
gist does not contact the reference centre immedi-
ately. However, based on this evaluation, we cannot
exclude the possibility that a vCJD case arising in
Belgium remains undetected. Therefore, we do not
have sufficient evidence to conclude that the surveil-
lance system meets its second main objective of de-
tecting vCJD cases arising in Belgium.
Only one third of neurologists were aware of the exist-
ence of the surveillance system and 22 % believed the
system lacks visibility and regular feedback to the data
providers. However, this does not indicate that neurolo-
gists do not refer cases to a reference centre. The lack of
association between referral behaviour of neurologists
and awareness of the surveillance system suggests that
referring cases or contacting a reference centre for diag-
nostic support is not done to contribute to the surveil-
lance system, but as part of good clinical practices.
Although the system is not well known, the majority of
data providers and public health officials considered
both vCJD and CJD surveillance at least important. This
suggests that CJD and vCJD surveillance are acceptable,
even in absence of the threat of a large vCJD epidemic.
Only nine (13 %) neurologists reported a decrease in
their participation or interest in CJD surveillance. Our
results suggest this may have impacted data quality,
which has been dropping since 1998.
Fig. 2 Importance of vCJD and CJD surveillance as reported by stakeholders, 2013, Belgium
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An important limitation of this evaluation lies in the
unknown representativeness of survey respondents.
Those with a special interest in CJD may have been
more likely to respond. The impact of this on our evalu-
ation cannot be estimated, and therefore the results of
the survey should be interpreted with caution and veri-
fied where possible. An example of the responder bias
might be represented in the difference between mea-
sured referral of suspect cases and self-reported referral
by neurologists. Sixty-eight percent of respondents said
they referred suspect CJD cases for autopsy. However,
when linking the hospital discharge data with the cases
referred for autopsy, only 50 % of cases were referred.
However, a possible alternative explanation for the dif-
ference between the estimated referral and the self-
reported referral may lie in a reporting error on hospital
level or an autopsy refusal of the family. Checking death
records of suspect CJD cases that did not undergo aut-
opsy in a reference centre would provide us with more
insight into referral practices and would perhaps allow
us to estimate the Belgian incidence more precisely.
Moreover, it could clarify the decrease in capture by the
surveillance system with increasing age.
Another limitation lies in the fact that some cases that
were referred for autopsy did not come from a hospital
setting. Indeed, not all patients that undergo autopsy
have died in hospital as some of them die at home or in
nursing homes. In this evaluation, we were not able to
estimate the proportion of suspect CJD cases referred
for autopsy from these settings. Therefore, we cannot be
certain that referral behaviour in another setting has not
changed over the years. However, we consider it unlikely
that referral behaviour would remain stable in one set-
ting and not in another.
Conclusions
In conclusion, the Belgian CJD surveillance system meets
one of its two main objectives: the system is capable of de-
tecting changes in CJD incidence in time, both at national
and regional level. Although self-reported referral behav-
iour of the Belgian neurologists indicates that vCJD cases
are likely to be captured by the surveillance system, this
evaluation does not give the necessary evidence that the
system meets its second objective of capturing vCJD cases.
The system was acceptable to data providers and public
health officials. Nevertheless, data providers consider the
lack of regular feedback and the current way of reporting
as the two main limitations to the system. Moreover, we
found that half of the suspect CJD cases were not referred
for autopsy and we found a decreasing trend in total cap-
ture over the years and a decreasing capture with age.
Therefore, we recommend to (a) revise the data reporting
through implementation of electronic tools (b) provide
regular feedback to reporting neurologists to enhance
their contribution, and (c) explore the reasons for not
undergoing autopsy, for example by performing a valid-
ation study on the CJD suspected deaths in hospital that
do not undergo autopsy.
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